Related Experiment Video
Updated: Feb 15, 2026

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients
Published on: March 1, 2024
Chemoprevention in Patients with Peutz-Jeghers Syndrome: Lessons Learned
Justin de Brabander1, Ferry A L M Eskens2, Susanne E Korsse3
1University of Amsterdam, Amsterdam, The Netherlands.
Lessons Learned:
Motivating patients to enroll in chemopreventive studies is challenging.Chemoprevention with toxic drugs is not feasible.
Background:
LKB1 mutations are the underlying genetic abnormality causing Peutz-Jeghers syndrome (PJS) and are a potential target for everolimus. In this phase II study, the efficacy of everolimus on polyp and tumor growth in PJS patients was investigated.
Methods:
Adult patients with a proven LKB1 mutation and who were suitable for everolimus treatment were included in two different PJS cohorts: (a) patients with unresectable malignancies and (b) patients with high-risk polyps. Treatment in both groups was oral everolimus, 10 mg daily. Response rates were primary endpoints for both cohorts.
Results:
Between October 2011 and April 2016, only two patients were enrolled, one in each cohort. A 49-year-old patient with advanced pancreatic cancer in cohort 1 was progressive after 2 months. A 52-year-old male patient in cohort 2 experienced severe toxicity and refused treatment after 4 months, even though endoscopy suggested stabilization of polyps. Adverse events included dental inflammations, mucositis, and rash. In 2016, the trial was aborted for lack of accrual, despite extensive accrual efforts in an area where PJS is highly prevalent and care is highly centralized.
Conclusion:
Due to accrual problems, no conclusions can be drawn about the value of everolimus in PJS treatment, questioning the feasibility of this agent for chemoprevention.
Insights
Enrollment challenges and severe toxicity in a phase II study question the feasibility of everolimus for chemoprevention in Peutz-Jeghers syndrome (PJS) patients with LKB1 mutations.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Peutz-Jeghers syndrome (PJS) is linked to LKB1 mutations.
- LKB1 mutations present a potential therapeutic target for everolimus.
Purpose of the Study:
- To investigate the efficacy of everolimus in managing polyp and tumor growth in PJS patients with LKB1 mutations.
Main Methods:
- A phase II study enrolled adult PJS patients with LKB1 mutations.
- Two cohorts were established: unresectable malignancies and high-risk polyps.
- Patients received oral everolimus (10 mg daily); response rates were primary endpoints.
Main Results:
- Only two patients enrolled between 2011 and 2016.
- One patient experienced disease progression; the other had severe toxicity and discontinued treatment.
- The trial was aborted due to insufficient patient accrual.
Conclusions:
- Accrual difficulties prevented conclusions on everolimus efficacy in PJS.
- The study raises concerns about the feasibility of everolimus for PJS chemoprevention.
Related Concept Videos
Avoidance Learning and Learned Helplessness
Avoidance learning occurs when an organism learns that a specific behavior can prevent an unpleasant outcome. For example, a student who receives a bad grade may start studying harder to avoid future poor grades. This behavior persists even when the negative outcome is no longer present. Avoidance learning is powerful because it maintains behavior in the absence of the...
Associative Learning
Classical conditioning, also known...
Purposive Learning
Observational Learning
Learning Disabilities
Dyslexia
Dyslexia is a...
Nephrotic Syndrome I : Introduction

